No Data
[2025 ASCO] Ascentage Pharma's core product APG-2575 received a verbal presentation, and the company had a total of two clinical studies selected.
Rockville, Maryland, USA and Suzhou, China, April 24, 2025 /PR Newswire/ -- Ayshan Pharma, a leading Biomedical company committed to developing Innovative Drugs in areas like blood cancers (Nasdaq code: AAPG; Hong Kong Stock Exchange code: 6855), today announced that results from two clinical studies of its key apoptosis pipeline products, the Bcl-2 selective inhibitor Lisaftoclax (APG-2575) and the MDM2-p53 inhibitor Alrizomadlin (APG-115), were selected for the 2025 American Clinical Oncology.
ASCENTAGE-B (06855) has two studies selected for the 2025 Annual Meeting of the American Society of Clinical Oncology, including an oral presentation of Lisaftoclax (APG-2575).
ASCENTAGE-B (06855) has released an announcement regarding the company's apoptosis pipeline key product, a Bcl-2 selective inhibitor...
Ascentage Pharma To Present Data From Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
Ascentage Drugs Included in Chinese Society of Clinical Oncology Guidelines; Shares Surge 13%
The Medical sector has frequently issued Bullish policies, leading to a significant increase in the Hang Seng Yinhua CSI Innovative Drugs Industry ETF, Hang Seng Biotechnology ETF, Hang Seng Medical Index ETF, and Hong Kong Stock Connect Medical ETF.
Innovative Drugs and Medical stocks in Hong Kong surged, with INNOCARE, SIMCERE PHARMA, and ASCENTAGE-B rising over 12%; Lepu Biopharma-B, CMS, CSPC PHARMA, INNOVENT BIO, and Hutchmed (China) increased by more than 7%.
2025 CSCO guideline update: ASCENTAGE-B (06855) APG-2575 is recommended for the first time, and Nairik has been upgraded to a recommendation.
ASCENTAGE-B (06855) announced that two of the company's self-developed blockbuster Innovative Drugs have been included in the 2025...
